CD8⁺ Tissue-Resident Memory T Cells in Health and Disease

Abstract

CD8⁺ tissue-resident memory T (T_RM) cells play a pivotal role in local immune regulation. These noncirculating T cells are uniquely positioned to orchestrate rapid site-specific immune responses, making them central to understanding tissue-specific immunity. Prior work has demonstrated that CD8⁺ T_RM cells possess dual functions: they are essential for immune defense against pathogens and malignancies, yet also drive pathological inflammation in autoimmune disorders. Furthermore, emerging evidence has begun to elucidate the intrinsic molecular mechanisms controlling this functional duality and to develop intervention strategies for its precise modulation. Here, we review current knowledge of the origin, transcriptional regulation, phenotypic characteristics, and functions of CD8⁺ T_RM cells. We discuss how T_RM cells correlate with clinical outcomes in diverse cancer types. Furthermore, we explore immune checkpoint inhibitors and other immunotherapies that target T_RM cells and their therapeutic implications from preclinical and translational human research. This review provides a comprehensive understanding of the molecular and cellular mechanisms governing T_RM cell activity and details their roles in health and disease. Ultimately, the framework of tissue immune networks reveals that leveraging T_RM cell development, tissue residency, and metabolism processes enables the design of innovative treatments for these diseases.

Keywords

antitumor immunity / autoimmune disease / tissue immunity / tissue-resident memory T cells / viral infection

References

[1] F. Sallusto, D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia, “Two Subsets of Memory T Lymphocytes With Distinct Homing Potentials and Effector Functions,” Nature 401, no. 6754 (1999): 708–712.

[2] F. Sallusto, J. Geginat, and A. Lanzavecchia, “Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance,” Annual Review of Immunology 22 (2004): 745–763.

[3] D. Masopust, V. Vezys, A. L. Marzo, and L. Lefrançois, “Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue,” Science 291, no. 5512 (2001): 2413–2417.

[4] R. J. Hogan, W. Zhong, E. J. Usherwood, T. Cookenham, A. D. Roberts, and D. L. Woodland, “Protection From respiratory Virus Infections Can be Mediated by Antigen-specific CD4(+) T Cells That Persist in the Lungs,” Journal of Experimental Medicine 193, no. 8 (2001): 981–986.

[5] R. J. Hogan, E. J. Usherwood, W. Zhong, et al., “Activated Antigen-Specific CD8+ T Cells Persist in the Lungs Following Recovery From Respiratory Virus Infections,” Journal of Immunology 166, no. 3 (2001): 1813–1822.

[6] T. Gebhardt, L. M. Wakim, L. Eidsmo, P. C. Reading, W. R. Heath, and F. R. Carbone, “Memory T Cells in Nonlymphoid Tissue That Provide Enhanced Local Immunity During Infection With Herpes Simplex Virus,” Nature Immunology 10, no. 5 (2009): 524–530.

[7] T. Sathaliyawala, M. Kubota, N. Yudanin, et al., “Distribution and Compartmentalization of Human Circulating and Tissue-Resident Memory T Cell Subsets,” Immunity 38, no. 1 (2013): 187–197.

[8] D. Masopust and L. J. Picker, “Hidden Memories: Frontline Memory T Cells and Early Pathogen Interception,” Journal of Immunology 188, no. 12 (2012): 5811–5817.

[9] B. S. Sheridan and L. Lefrançois, “Regional and Mucosal Memory T Cells,” Nature Immunology 12, no. 6 (2011): 485–491.

[10] X. Jiang, R. A. Clark, L. Liu, A. J. Wagers, R. C. Fuhlbrigge, and T. S. Kupper, “Skin Infection Generates Non-Migratory Memory CD8+ T(RM) Cells Providing Global Skin Immunity,” Nature 483, no. 7388 (2012): 227–231.

[11] L. K. Mackay, A. Rahimpour, J. Z. Ma, et al., “The Developmental Pathway for CD103(+)CD8+ Tissue-Resident Memory T Cells of Skin,” Nature Immunology 14, no. 12 (2013): 1294–1301.

[12] E. C. Reilly, K. Lambert Emo, and P. M. Buckley, “T(RM) Integrins CD103 and CD49a Differentially Support Adherence and Motility After Resolution of Influenza Virus Infection,” PNAS 117, no. 22 (2020): 12306–12314.

[13] L. M. Wakim, A. Woodward-Davis, and M. J. Bevan, “Memory T Cells Persisting Within the Brain After Local Infection Show Functional Adaptations to Their Tissue of Residence,” PNAS USA 107, no. 42 (2010): 17872–17879.

[14] K. G. Anderson, H. Sung, C. N. Skon, et al., “Cutting Edge: Intravascular Staining Redefines Lung CD8 T Cell Responses,” Journal of Immunology 189, no. 6 (2012): 2702–2706.

[15] D. Fernandez-Ruiz, W. Y. Ng, L. E. Holz, et al., “Liver-Resident Memory CD8(+) T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection,” Immunity 45, no. 4 (2016): 889–902.

[16] K. A. Casey, K. A. Fraser, J. M. Schenkel, et al., “Antigen-Independent Differentiation and Maintenance of Effector-Like Resident Memory T Cells in Tissues,” Journal of Immunology 188, no. 10 (2012): 4866–4875.

[17] M. Hofmann and H. Pircher, “E-Cadherin Promotes Accumulation of a Unique Memory CD8 T-Cell Population in Murine Salivary Glands,” PNAS 108, no. 40 (2011): 16741–16746.

[18] D. Masopust, D. Choo, V. Vezys, et al., “Dynamic T Cell Migration Program Provides Resident Memory Within Intestinal Epithelium,” Journal of Experimental Medicine 207, no. 3 (2010): 553–564.

[19] V. A. Tang and K. L. Rosenthal, “Intravaginal Infection With Herpes Simplex Virus Type-2 (HSV-2) Generates a Functional Effector Memory T Cell Population That Persists in the Murine Genital Tract,” Journal of Reproductive Immunology 87, no. 1-2 (2010): 39–44.

[20] J. T. Crowl, M. Heeg, A. Ferry, et al., “Tissue-Resident Memory CD8(+) T Cells Possess Unique Transcriptional, Epigenetic and Functional Adaptations to Different Tissue Environments,” Nature Immunology 23, no. 7 (2022): 1121–1131.

[21] J. J. Milner, C. Toma, B. Yu, et al., “Runx3 Programs CD8(+) T Cell Residency in Non-Lymphoid Tissues and Tumours,” Nature 552, no. 7684 (2017): 253–257.

[22] L. K. Mackay, M. Minnich, N. A. Kragten, et al., “Hobit and Blimp1 Instruct a Universal Transcriptional Program of Tissue Residency in Lymphocytes,” Science 352, no. 6284 (2016): 459–463.

[23] C. S. Boddupalli, S. Nair, S. M. Gray, et al., “ABC Transporters and NR4A1 Identify a Quiescent Subset of Tissue-Resident Memory T Cells,” Journal of Clinical Investigation 126, no. 10 (2016): 3905–3916.

[24] D. Amsen, K. van Gisbergen, P. Hombrink, and R. A. W. van Lier, “Tissue-Resident Memory T Cells at the Center of Immunity to Solid Tumors,” Nature Immunology 19, no. 6 (2018): 538–546.

[25] N. Dumauthioz, S. Labiano, and P. Romero, “Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy,” Frontiers in Immunology 9 (2018): 2076.

[26] S. C. Sasson, C. L. Gordon, S. N. Christo, P. Klenerman, and L. K. Mackay, “Local Heroes or Villains: Tissue-Resident Memory T Cells in Human Health and Disease,” Cellular & Molecular Immunology 17, no. 2 (2020): 113–122.

[27] A. Byrne, P. Savas, S. Sant, et al., “Tissue-resident Memory T Cells in Breast Cancer Control and Immunotherapy Responses,” Nature Reviews Clinical Oncology 17, no. 6 (2020): 341–348.

[28] B. Virassamy, F. Caramia, P. Savas, et al., “Intratumoral CD8(+) T Cells With a Tissue-Resident Memory Phenotype Mediate Local Immunity and Immune Checkpoint Responses in Breast Cancer,” Cancer Cell 41, no. 3 (2023): 585–601, e8.

[29] Z. X. Wu, T. T. Da, C. Huang, et al., “CD69(+)CD103(+)CD8(+) Tissue-Resident Memory T Cells Possess Stronger Anti-Tumor Activity and Predict Better Prognosis in Colorectal Cancer,” Cell Communication and Signaling 22, no. 1 (2024): 608.

[30] F. Jiang, M. Mao, S. Jiang, Y. Jiao, D. Cao, and Y. Xiang, “PD-1 and TIGIT Coexpressing CD8 + CD103 + Tissue-Resident Memory Cells in Endometrial Cancer as Potential Targets for Immunotherapy,” International Immunopharmacology 127 (2024): 111381.

[31] F. L. Komdeur, M. C. Wouters, H. H. Workel, et al., “CD103+ Intraepithelial T Cells in High-Grade Serous Ovarian Cancer Are Phenotypically Diverse TCRαβ+ CD8αβ+ T Cells That Can be Targeted for Cancer Immunotherapy,” Oncotarget 7, no. 46 (2016): 75130–75144.

[32] F. L. Komdeur, T. M. Prins, S. van de Wall, et al., “CD103+ Tumor-Infiltrating Lymphocytes Are Tumor-Reactive Intraepithelial CD8+ T Cells Associated With Prognostic Benefit and Therapy Response in Cervical Cancer,” Oncoimmunology 6, no. 9 (2017): e1338230.

[33] K. Jin, Y. Yu, H. Zeng, et al., “CD103(+)CD8(+) Tissue-resident Memory T Cell Infiltration Predicts Clinical Outcome and Adjuvant Therapeutic Benefit in Muscle-Invasive Bladder Cancer,” British Journal of Cancer 126, no. 11 (2022): 1581–1588.

[34] M. K. Maini and A. R. Burton, “Restoring, Releasing or Replacing Adaptive Immunity in Chronic Hepatitis B,” Nature Reviews Gastroenterology & Hepatology 16, no. 11 (2019): 662–675.

[35] M. Ganley, L. E. Holz, J. J. Minnell, et al., “mRNA Vaccine Against Malaria Tailored for Liver-Resident Memory T Cells,” Nature Immunology 24, no. 9 (2023): 1487–1498.

[36] K. Sugahara, Y. Maeda, K. Shimano, et al., “Amiselimod, a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Has Potent Therapeutic Efficacy for Autoimmune Diseases, With Low Bradycardia Risk,” British Journal of Pharmacology 174, no. 1 (2017): 15–27.

[37] M. Zhou, C. Guo, X. Li, et al., “JAK/STAT Signaling Controls the Fate of CD8(+)CD103(+) Tissue-Resident Memory T Cell in Lupus Nephritis,” Journal of Autoimmunity 109 (2020): 102424.

[38] J. M. Richmond, J. P. Strassner, L. Zapata, Jr., et al., “Antibody Blockade of IL-15 Signaling Has the Potential to Durably Reverse Vitiligo,” Science Translational Medicine 10, no. 450 (2018): eaam7710.

[39] V. M. Belkin, A. M. Belkin, and V. E. Koteliansky, “Human Smooth Muscle VLA-1 Integrin: Purification, Substrate Specificity, Localization in Aorta, and Expression During Development,” Journal of Cell Biology 111, no. 5 Pt 1 (1990): 2159–2170.

[40] S. Cheuk, H. Schlums, I. Gallais Sérézal, et al., “CD49a Expression Defines Tissue-Resident CD8(+) T Cells Poised for Cytotoxic Function in Human Skin,” Immunity 46, no. 2 (2017): 287–300.

[41] T. Murray, S. A. Fuertes Marraco, P. Baumgaertner, et al., “Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates With Survival of Melanoma Patients,” Frontiers in immunology 7 (2016): 573.

[42] S. Corgnac, M. Boutet, M. Kfoury, C. Naltet, and F. Mami-Chouaib, “The Emerging Role of CD8(+) Tissue Resident Memory T (T(RM)) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin,” Frontiers in immunology 9 (2018): 1904.

[43] K. L. Cepek, S. K. Shaw, C. M. Parker, et al., “Adhesion Between Epithelial Cells and T Lymphocytes Mediated by E-Cadherin and the Alpha E Beta 7 Integrin,” Nature 372, no. 6502 (1994): 190–193.

[44] L. K. Mackay, A. Braun, B. L. Macleod, et al., “Cutting Edge: CD69 Interference With Sphingosine-1-Phosphate Receptor Function Regulates Peripheral T Cell Retention,” Journal of Immunology 194, no. 5 (2015): 2059–2063.

[45] H. Chen, Y. Qin, M. Chou, J. G. Cyster, and X. Li, “Transmembrane Protein CD69 acts as an S1PR1 Agonist,” Elife 12 (2023), Apr 11: e88204.

[46] E. Menares, F. Gálvez-Cancino, P. Cáceres-Morgado, et al., “Tissue-Resident Memory CD8(+) T Cells Amplify Anti-Tumor Immunity by Triggering Antigen Spreading Through Dendritic Cells,” Nature Communications 10, no. 1 (2019): 4401.

[47] C. N. Skon, J. Y. Lee, K. G. Anderson, D. Masopust, K. A. Hogquist, and S. C. Jameson, “Transcriptional Downregulation of S1pr1 Is Required for the Establishment of Resident Memory CD8+ T Cells,” Nature Immunology 14, no. 12 (2013): 1285–1293.

[48] W. Piao, Z. L. Lee, G. Zapas, et al., “Regulatory T Cell and Endothelial Cell Crosstalk,” Nature Reviews Immunology (2025), Apr 1: 588–607.

[49] A. J. Bankovich, L. R. Shiow, and J. G. Cyster, “CD69 Suppresses Sphingosine 1-Phosophate Receptor-1 (S1P1) Function Through Interaction With Membrane Helix 4,” Journal of Biological Chemistry 285, no. 29 (2010): 22328–22337.

[50] J. M. Schenkel and D. Masopust, “Tissue-Resident Memory T Cells,” Immunity 41, no. 6 (2014): 886–897.

[51] G. Kueberuwa, H. Gornall, E. M. Alcantar-Orozco, et al., “CCR7(+) Selected Gene-Modified T Cells Maintain a Central Memory Phenotype and Display Enhanced Persistence in Peripheral Blood in Vivo,” Journal for ImmunoTherapy of Cancer 5 (2017): 14.

[52] A. Rot and U. H. von Andrian, “Chemokines in Innate and Adaptive Host Defense: Basic Chemokinese Grammar for Immune Cells,” Annual Review of Immunology 22 (2004): 891–928.

[53] R. Förster, A. C. Davalos-Misslitz, and A. Rot, “CCR7 and Its Ligands: Balancing Immunity and Tolerance,” Nature Reviews Immunology 8, no. 5 (2008): 362–371.

[54] S. N. Mueller and L. K. Mackay, “Tissue-resident Memory T Cells: Local Specialists in Immune Defence,” Nature Reviews Immunology 16, no. 2 (2016): 79–89.

[55] L. K. Mackay, A. T. Stock, J. Z. Ma, et al., “Long-Lived Epithelial Immunity by Tissue-resident Memory T (TRM) Cells in the Absence of Persisting Local Antigen Presentation,” PNAS USA 109, no. 18 (2012): 7037–7042.

[56] M. V. Richter and D. J. Topham, “The alpha1beta1 Integrin and TNF Receptor II Protect Airway CD8+ Effector T Cells From Apoptosis During Influenza Infection,” Journal of Immunology 179, no. 8 (2007): 5054–5063.

[57] S. J. Ray, S. N. Franki, R. H. Pierce, et al., “The Collagen Binding alpha1beta1 Integrin VLA-1 Regulates CD8 T Cell-Mediated Immune Protection Against Heterologous Influenza Infection,” Immunity 20, no. 2 (2004): 167–179.

[58] R. Reschke, J. Yu, B. Flood, E. F. Higgs, K. Hatogai, and T. F. Gajewski, “Immune Cell and Tumor Cell-Derived CXCL10 Is Indicative of Immunotherapy Response in Metastatic Melanoma,” Journal for ImmunoTherapy of Cancer 9, no. 9 (2021): e003521.

[59] X. Guo, Y. Zhang, L. Zheng, et al., “Global Characterization of T Cells in Non-Small-Cell Lung Cancer by Single-Cell Sequencing,” Nature Medicine 24, no. 7 (2018): 978–985.

[60] M. Sade-Feldman, K. Yizhak, S. L. Bjorgaard, et al., “Defining T Cell States Associated With Response to Checkpoint Immunotherapy in Melanoma,” Cell 175, no. 4 (2018): 998–1013, e20.

[61] I. Tirosh, B. Izar, S. M. Prakadan, et al., “Dissecting the Multicellular Ecosystem of Metastatic Melanoma by Single-Cell RNA-seq,” Science 352, no. 6282 (2016): 189–196.

[62] H. Chi, M. Pepper, and P. G. Thomas, “Principles and Therapeutic Applications of Adaptive Immunity,” Cell 187, no. 9 (2024): 2052–2078.

[63] L. Rausch and A. Kallies, “Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer,” Annual Review of Immunology 43, no. 1 (2025): 515–543.

[64] S. M. Kaech and W. Cui, “Transcriptional Control of Effector and Memory CD8+ T Cell Differentiation,” Nature Reviews Immunology 12, no. 11 (2012): 749–761.

[65] L. Kok, D. Masopust, and T. N. Schumacher, “The Precursors of CD8(+) Tissue Resident Memory T Cells: From Lymphoid Organs to Infected Tissues,” Nature Reviews Immunology 22, no. 5 (2022): 283–293.

[66] H. Li, A. M. van der Leun, I. Yofe, et al., “Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma,” Cell 176, no. 4 (2019): 775–789, e18.

[67] J. Li, C. Xiao, C. Li, and J. He, “Tissue-Resident Immune Cells: From Defining Characteristics to Roles in Diseases,” Signal Transduction Target Therapy 10, no. 1 (2025): 12.

[68] H. Xu, R. Zhou, and Z. Chen, “Tissue-Resident Memory T Cell: Ontogenetic Cellular Mechanism and Clinical Translation,” Clinical and Experimental Immunology 214, no. 3 (2023): 249–259.

[69] L. Chen and Z. Shen, “Tissue-resident Memory T Cells and Their Biological Characteristics in the Recurrence of Inflammatory Skin Disorders,” Cellular & Molecular Immunology 17, no. 1 (2020): 64–75.

[70] N. S. Joshi, W. Cui, A. Chandele, et al., “Inflammation Directs Memory Precursor and Short-Lived Effector CD8(+) T Cell Fates Via the Graded Expression of T-bet Transcription Factor,” Immunity 27, no. 2 (2007): 281–295.

[71] J. T. Chang, E. J. Wherry, and A. W. Goldrath, “Molecular Regulation of Effector and Memory T Cell Differentiation,” Nature Immunology 15, no. 12 (2014): 1104–1115.

[72] J. L. Reading, F. Gálvez-Cancino, C. Swanton, A. Lladser, K. S. Peggs, and S. A. Quezada, “The Function and Dysfunction of Memory CD8(+) T Cells in Tumor Immunity,” Immunological Reviews 283, no. 1 (2018): 194–212.

[73] H. G. Woon, A. Braun, J. Li, et al., “Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs,” Plos Pathogens 12, no. 8 (2016): e1005799.

[74] F. A. Vieira Braga, K. M. Hertoghs, N. A. Kragten, et al., “Blimp-1 Homolog Hobit Identifies Effector-Type Lymphocytes in Humans,” European Journal of Immunology 45, no. 10 (2015): 2945–2958.

[75] B. Grueter, M. Petter, T. Egawa, et al., “Runx3 regulates Integrin Alpha E/CD103 and CD4 Expression During Development of CD4-/CD8+ T Cells,” Journal of Immunology 175, no. 3 (2005): 1694–1705.

[76] F. Cruz-Guilloty, M. E. Pipkin, I. M. Djuretic, et al., “Runx3 and T-box Proteins Cooperate to Establish the Transcriptional Program of Effector CTLs,” Journal of Experimental Medicine 206, no. 1 (2009): 51–59.

[77] Q. Shan, Z. Zeng, S. Xing, et al., “The Transcription Factor Runx3 Guards Cytotoxic CD8(+) Effector T Cells Against Deviation Towards Follicular Helper T Cell Lineage,” Nature Immunology 18, no. 8 (2017): 931–939.

[78] Z. Liu, X. Li, Y. Gao, et al., “Epigenetic Reprogramming of Runx3 Reinforces CD8 + T-Cell Function and Improves the Clinical Response to Immunotherapy,” Molecular cancer 22, no. 1 (2023): 84.

[79] D. Wang, H. Diao, A. J. Getzler, et al., “The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation,” Immunity 48, no. 4 (2018): 659–674, e6.

[80] R. Fonseca, T. N. Burn, L. C. Gandolfo, et al., “Runx3 Drives a CD8(+) T Cell Tissue Residency Program That Is Absent in CD4(+) T Cells,” Nature Immunology 23, no. 8 (2022): 1236–1245.

[81] M. E. Cook, N. N. Jarjour, C. C. Lin, and B. T. Edelson, “Transcription Factor Bhlhe40 in Immunity and Autoimmunity,” Trends in Immunology 41, no. 11 (2020): 1023–1036.

[82] B. St-Pierre, G. Flock, E. Zacksenhaus, and S. E. Egan, “Stra13 homodimers Repress Transcription Through Class B E-box Elements,” Journal of Biological Chemistry 277, no. 48 (2002): 46544–46551.

[83] J. P. Huynh, C. C. Lin, J. M. Kimmey, et al., “Bhlhe40 is an Essential Repressor of IL-10 During Mycobacterium Tuberculosis Infection,” Journal of Experimental Medicine 215, no. 7 (2018): 1823–1838.

[84] C. Li, B. Zhu, Y. M. Son, et al., “The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8(+) T Cell Fitness and Functionality,” Immunity 51, no. 3 (2019): 491–507.e7.

[85] C. H. Chang, J. Qiu, D. O'Sullivan, et al., “Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression,” Cell 162, no. 6 (2015): 1229–1241.

[86] S. P. Colgan, E. L. Campbell, and D. J. Kominsky, “Hypoxia and Mucosal Inflammation,” Annual Review of Pathology 11 (2016): 77–100.

[87] E. L. Pearce, A. C. Mullen, G. A. Martins, et al., “Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin,” Science 302, no. 5647 (2003): 1041–1043.

[88] M. Buggert, J. Tauriainen, T. Yamamoto, et al., “T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection,” Plos Pathogens 10, no. 7 (2014): e1004251.

[89] R. R. Rao, Q. Li, K. Odunsi, and P. A. Shrikant, “The mTOR Kinase Determines Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin,” Immunity 32, no. 1 (2010): 67–78.

[90] A. Banerjee, S. M. Gordon, A. M. Intlekofer, et al., “Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells to Compete for the Memory Cell Niche,” Journal of Immunology 185, no. 9 (2010): 4988–4992.

[91] L. K. Mackay, E. Wynne-Jones, D. Freestone, et al., “T-box Transcription Factors Combine with the Cytokines TGF-β and IL-15 to Control Tissue-Resident Memory T Cell Fate,” Immunity 43, no. 6 (2015): 1101–1111.

[92] L. Wang, S. Mishra, K. K. Fan, et al., “T-bet Deficiency and Hic1 Induction Override TGF-β-Dependency in the Formation of CD103(+) Intestine-Resident Memory CD8(+) T Cells,” Cell Reports 43, no. 6 (2024): 114258.

[93] Y. H. Lin, H. G. Duong, A. E. Limary, et al., “Small Intestine and Colon Tissue-Resident Memory CD8(+) T Cells Exhibit Molecular Heterogeneity and Differential Dependence on Eomes,” Immunity 56, no. 1 (2023): 207–223, e8.

[94] M. Reina-Campos, A. Monell, A. Ferry, et al., “Tissue-Resident Memory CD8 T Cell Diversity is Spatiotemporally Imprinted,” Nature 639, no. 8054 (2025): 483–492.

[95] N. Zhang and M. J. Bevan, “Transforming Growth Factor-β Signaling Controls the Formation and Maintenance of Gut-Resident Memory T Cells by Regulating Migration and Retention,” Immunity 39, no. 4 (2013): 687–696.

[96] L. M. Wakim, J. Smith, I. Caminschi, M. H. Lahoud, and J. A. Villadangos, “Antibody-Targeted Vaccination to Lung Dendritic Cells Generates Tissue-Resident Memory CD8 T Cells That Are Highly Protective Against Influenza Virus Infection,” Mucosal Immunol 8, no. 5 (2015): 1060–1071.

[97] Y. Koda, T. Teratani, P. S. Chu, et al., “CD8(+) tissue-resident Memory T Cells Promote Liver Fibrosis Resolution by Inducing Apoptosis of Hepatic Stellate Cells,” Nature Communications 12, no. 1 (2021): 4474.

[98] Y. Qin, B. S. Garrison, W. Ma, et al., “A Milieu Molecule for TGF-β Required for Microglia Function in the Nervous System,” Cell 174, no. 1 (2018): 156–171.e16.

[99] I. B. Robertson and D. B. Rifkin, “Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins,” Cold Spring Harbor perspectives in biology 8, no. 6 (2016): a021907.

[100] V. Mani, S. K. Bromley, T. Äijö, et al., “Migratory DCs Activate TGF-β to Precondition Naïve CD8(+) T Cells for Tissue-Resident Memory Fate,” Science 366, no. 6462 (2019): eaav5728.

[101] H. Zhao, J. Wei, and J. Sun, “Roles of TGF-β Signaling Pathway in Tumor Microenvironment and Cancer Therapy,” International Immunopharmacology 89, no. Pt B (2020): 107101.

[102] A. W. Goldrath, P. V. Sivakumar, M. Glaccum, et al., “Cytokine Requirements for Acute and Basal Homeostatic Proliferation of Naive and Memory CD8+ T Cells,” Journal of Experimental Medicine 195, no. 12 (2002): 1515–1522.

[103] B. Jabri and V. Abadie, “IL-15 Functions as a Danger Signal to Regulate Tissue-Resident T Cells and Tissue Destruction,” Nature Reviews Immunology 15, no. 12 (2015): 771–783.

[104] R. Tieu, Q. Zeng, D. Zhao, et al., “Tissue-resident Memory T Cell Maintenance During Antigen Persistence Requires both Cognate Antigen and Interleukin-15,” Science Immunology 8, no. 82 (2023): eadd8454.

[105] R. M. Teague, B. D. Sather, J. A. Sacks, et al., “Interleukin-15 Rescues Tolerant CD8+ T Cells for Use in Adoptive Immunotherapy of Established Tumors,” Nature Medicine 12, no. 3 (2006): 335–341.

[106] B. Mlecnik, G. Bindea, H. K. Angell, et al., “Functional Network Pipeline Reveals Genetic Determinants Associated With in Situ Lymphocyte Proliferation and Survival of Cancer Patients,” Science Translational Medicine 6, no. 228 (2014): 228ra37.

[107] K. C. Verbist, C. J. Cole, M. B. Field, and K. D. Klonowski, “A Role for IL-15 in the Migration of Effector CD8 T Cells to the Lung Airways Following Influenza Infection,” Journal of Immunology 186, no. 1 (2011): 174–182.

[108] R. T. Sowell, J. W. Goldufsky, M. Rogozinska, et al., “IL-15 Complexes Induce Migration of Resting Memory CD8 T Cells Into Mucosal Tissues,” Journal of Immunology 199, no. 7 (2017): 2536–2546.

[109] M. Reina-Campos, M. Heeg, and K. Kennewick, “Metabolic Programs of T Cell Tissue Residency Empower Tumour Immunity,” Nature 621, no. 7977 (2023): 179–187.

[110] D. Mantle, L. Millichap, J. Castro-Marrero, and I. P. Hargreaves, “Primary Coenzyme Q10 Deficiency: An Update,” Antioxidants (Basel) 12, no. 8 (2023): 1652.

[111] Y. Tang, Z. Chen, Q. Zuo, and Y. Kang, “Regulation of CD8+ T Cells by Lipid Metabolism in Cancer Progression,” Cellular & Molecular Immunology 21, no. 11 (2024): 1215–1230.

[112] M. D. Buck, D. O'Sullivan, and E. L. Pearce, “T Cell Metabolism Drives Immunity,” Journal of Experimental Medicine 212, no. 9 (2015): 1345–1360.

[113] T. Vardam-Kaur, J. Sun, and H. Borges da Silva, “Metabolic Regulation of Tissue-Resident Memory CD8(+) T Cells,” Current Opinion in Pharmacology 57 (2021): 117–124.

[114] G. J. van der Windt, D. O'Sullivan, and B. Everts, “CD8 memory T Cells Have a Bioenergetic Advantage That Underlies Their Rapid Recall Ability,” PNAS USA 110, no. 35 (2013): 14336–14341.

[115] G. Cui, M. M. Staron, S. M. Gray, et al., “IL-7-Induced Glycerol Transport and TAG Synthesis Promotes Memory CD8+ T Cell Longevity,” Cell 161, no. 4 (2015): 750–761.

[116] Y. Zhang, Q. Li, E. Rao, et al., “Epidermal Fatty Acid Binding Protein Promotes Skin Inflammation Induced By High-Fat Diet,” Immunity 42, no. 5 (2015): 953–964.

[117] D. Khnykin, J. H. Miner, and F. Jahnsen, “Role of Fatty Acid Transporters in Epidermis: Implications for Health and Disease,” Dermato-Endocrinology 3, no. 2 (2011): 53–61.

[118] Y. Pan, T. Tian, C. O. Park, et al., “Survival of Tissue-Resident Memory T Cells Requires Exogenous Lipid Uptake and Metabolism,” Nature 543, no. 7644 (2017): 252–256.

[119] Y. Pan and T. S. Kupper, “Metabolic Reprogramming and Longevity of Tissue-Resident Memory T Cells,” Frontiers in Immunology 9 (2018): 1347.

[120] H. Frizzell, R. Fonseca, S. N. Christo, et al., “Organ-Specific Isoform Selection of Fatty Acid-Binding Proteins in Tissue-Resident Lymphocytes,” Science Immunology 5, no. 46 (2020): eaay9283.

[121] G. S. Hotamisligil and D. A. Bernlohr, “Metabolic Functions of FABPs–Mechanisms and Therapeutic Implications,” Nature Reviews Endocrinology 11, no. 10 (2015): 592–605.

[122] M. A. Freitas-Cortez, F. Masrorpour, H. Jiang, et al., “Cancer Cells Avoid Ferroptosis Induced by Immune Cells via Fatty Acid Binding Proteins,” Molecular Cancer 24, no. 1 (2025): 40.

[123] T. T. Kim and J. R. Dyck, “The Role of CD36 in the Regulation of Myocardial Lipid Metabolism,” Biochimica Et Biophysica Acta 1861, no. 10 (2016): 1450–1460.

[124] H. Wang, F. Franco, Y. C. Tsui, et al., “CD36-mediated Metabolic Adaptation Supports Regulatory T Cell Survival and Function in Tumors,” Nature Immunology 21, no. 3 (2020): 298–308.

[125] R. L. Silverstein and M. Febbraio, “CD36 and Atherosclerosis,” Current Opinion in Lipidology 11, no. 5 (2000): 483–491.

[126] M. Y. Pepino, O. Kuda, D. Samovski, and N. A. Abumrad, “Structure-Function of CD36 and Importance of Fatty Acid Signal Transduction in Fat Metabolism,” Annual Review of Nutrition 34 (2014): 281–303.

[127] C. Han, M. Ge, P. Xing, et al., “Cystine Deprivation Triggers CD36-mediated Ferroptosis and Dysfunction of Tumor Infiltrating CD8(+) T Cells,” Cell Death & Disease 15, no. 2 (2024): 145.

[128] J. M. Schenkel, K. A. Fraser, V. Vezys, and D. Masopust, “Sensing and Alarm Function of Resident Memory CD8⁺ T Cells,” Nature Immunology 14, no. 5 (2013): 509–513.

[129] S. Ariotti, M. A. Hogenbirk, F. E. Dijkgraaf, et al., “T Cell Memory. Skin-Resident Memory CD8⁺ T Cells Trigger a state of Tissue-Wide Pathogen Alert,” Science 346, no. 6205 (2014): 101–105.

[130] G. S. Cooke, B. Flower, E. Cunningham, et al., “Progress Towards Elimination of Viral hepatitis: A Lancet Gastroenterology & Hepatology Commission Update,” Lancet Gastroenterology Hepatology 9, no. 4 (2024): 346–365.

[131] P. Van Damme, R. M. Pintó, Z. Feng, F. Cui, A. Gentile, and D. Shouval, “Hepatitis A Virus Infection,” Nature Reviews Disease Primers 9, no. 1 (2023): 51.

[132] W. J. Jeng, G. V. Papatheodoridis, and A. S. F. Lok, “Hepatitis B,” Lancet 401, no. 10381 (2023): 1039–1052.

[133] M. P. Manns, M. Buti, E. Gane, et al., “Hepatitis C Virus Infection,” Nature Reviews Disease Primers 3 (2017): 17006.

[134] L. J. Pallett, J. Davies, E. J. Colbeck, et al., “IL-2(High) Tissue-Resident T Cells in the Human Liver: Sentinels for Hepatotropic Infection,” Journal of Experimental Medicine 214, no. 6 (2017): 1567–1580.

[135] C. C. Sung, J. H. Horng, S. H. Siao, et al., “Asialo GM1-Positive Liver-Resident CD8 T Cells That Express CD44 and LFA-1 Are Essential for Immune Clearance of Hepatitis B Virus,” Cellular & Molecular Immunology 18, no. 7 (2021): 1772–1782.

[136] J. Kim, D. Y. Chang, H. W. Lee, et al., “Innate-like Cytotoxic Function of Bystander-Activated CD8(+) T Cells Is Associated with Liver Injury in Acute Hepatitis A,” Immunity 48, no. 1 (2018): 161–173, e5.

[137] H. Kefalakes, X. J. Horgan, M. K. Jung, et al., “Liver-Resident Bystander CD8(+) T Cells Contribute to Liver Disease Pathogenesis in Chronic Hepatitis D Virus Infection,” Gastroenterology 161, no. 5 (2021): 1567–1583.e9.

[138] Y. Cheng, B. Gunasegaran, H. D. Singh, et al., “Non-Terminally Exhausted Tumor-Resident Memory HBV-Specific T Cell Responses Correlate With Relapse-Free Survival in Hepatocellular Carcinoma,” Immunity 54, no. 8 (2021): 1825–1840.e7.

[139] J. Wei and J. J. Ishizuka, “Going Viral: HBV-Specific CD8(+) Tissue-Resident Memory T Cells Propagate Anti-Tumor Immunity,” Immunity 54, no. 8 (2021): 1630–1632.

[140] R. G. Webster and E. A. Govorkova, “Continuing Challenges in Influenza,” Annals of the New York Academy of Sciences 1323, no. 1 (2014): 115–139.

[141] M. Z. M. Zheng and L. M. Wakim, “Tissue Resident Memory T Cells in the respiratory Tract,” Mucosal Immunology 15, no. 3 (2022): 379–388.

[142] T. Wu, Y. Hu, Y. T. Lee, et al., “Lung-resident Memory CD8 T Cells (TRM) Are Indispensable for Optimal Cross-protection Against Pulmonary Virus Infection,” Journal of Leukocyte Biology 95, no. 2 (2014): 215–224.

[143] S. R. McMaster, J. J. Wilson, H. Wang, and J. E. Kohlmeier, “Airway-Resident Memory CD8 T Cells Provide Antigen-Specific Protection Against Respiratory Virus Challenge Through Rapid IFN-γ Production,” Journal of Immunology 195, no. 1 (2015): 203–209.

[144] X. Wu, P. Wu, Y. Shen, X. Jiang, and F. Xu, “CD8(+) Resident Memory T Cells and Viral Infection,” Frontiers in Immunology 9 (2018): 2093.

[145] P. Gilchuk, T. M. Hill, C. Guy, et al., “A Distinct Lung-Interstitium-Resident Memory CD8(+) T Cell Subset Confers Enhanced Protection to Lower Respiratory Tract Infection,” Cell Reports 16, no. 7 (2016): 1800–1809.

[146] A. Pizzolla, T. H. O. Nguyen, J. M. Smith, et al., “Resident Memory CD8(+) T Cells in the Upper Respiratory Tract Prevent Pulmonary Influenza Virus Infection,” Science Immunology 2, no. 12 (2017): eaam6970.

[147] A. Yoshizawa, K. Bi, D. B. Keskin, G. Zhang, B. Reinhold, and E. L. Reinherz, “TCR-pMHC Encounter Differentially Regulates Transcriptomes of Tissue-Resident CD8 T Cells,” European Journal of Immunology 48, no. 1 (2018): 128–150.

[148] P. A. Szabo, P. Dogra, J. I. Gray, et al., “Longitudinal Profiling of Respiratory and Systemic Immune Responses Reveals Myeloid Cell-Driven Lung Inflammation in Severe COVID-19,” Immunity 54, no. 4 (2021): 797–814, e6.

[149] A. Zhu, Z. Chen, Q. Yan, et al., “Robust Mucosal SARS-CoV-2-Specific T Cells Effectively Combat COVID-19 and Establish Polyfunctional Resident Memory in Patient Lungs,” Nature Immunology 26, no. 3 (2025): 459–472.

[150] J. Grau-Expósito, N. Sánchez-Gaona, N. Massana, et al., “Peripheral and Lung Resident Memory T Cell Responses Against SARS-CoV-2,” Nature Communications 12, no. 1 (2021): 3010.

[151] A. Mody, A. H. Sohn, C. Iwuji, R. K. J. Tan, F. Venter, and E. H. Geng, “HIV Epidemiology, Prevention, Treatment, and Implementation Strategies for Public Health,” Lancet 403, no. 10425 (2024): 471–492.

[152] S. A. Migueles and M. Connors, “Success and Failure of the Cellular Immune Response Against HIV-1,” Nature Immunology 16, no. 6 (2015): 563–570.

[153] M. Buggert, S. Nguyen, G. Salgado-Montes de Oca, et al., “Identification and Characterization of HIV-Specific Resident Memory CD8(+) T Cells in human Lymphoid Tissue,” Science Immunology 3, no. 24 (2018): eaar4526.

[154] M. A. Reuter, P. M. Del Rio Estrada, M. Buggert, et al., “HIV-Specific CD8(+) T Cells Exhibit Reduced and Differentially Regulated Cytolytic Activity in Lymphoid Tissue,” Cell Reports 21, no. 12 (2017): 3458–3470.

[155] A. Gibbs, M. Buggert, G. Edfeldt, et al., “Human Immunodeficiency Virus-Infected Women Have High Numbers of CD103-CD8+ T Cells Residing Close to the Basal Membrane of the Ectocervical Epithelium,” Journal of Infectious Diseases 218, no. 3 (2018): 453–465.

[156] D. C. Moylan, P. A. Goepfert, M. C. Kempf, et al., “Diminished CD103 (αEβ7) Expression on Resident T Cells From the Female Genital Tract of HIV-Positive Women,” Pathogens and Immunity Fall-Winter 1, no. 2 (2016): 371–387.

[157] B. E. Kiniry, S. Li, A. Ganesh, et al., “Detection of HIV-1-Specific Gastrointestinal Tissue Resident CD8(+) T-Cells in Chronic Infection,” Mucosal Immunology 11, no. 3 (2018): 909–920.

[158] B. E. Kiniry, A. Ganesh, J. W. Critchfield, et al., “Predominance of Weakly Cytotoxic, T-bet(Low)Eomes(Neg) CD8(+) T-cells in Human Gastrointestinal Mucosa: Implications for HIV Infection,” Mucosal Immunology 10, no. 4 (2017): 1008–1020.

[159] M. Lecuit, “Listeria Monocytogenes, a Model in Infection Biology,” Cellular Microbiology 22, no. 4 (2020): e13186.

[160] L. Radoshevich and P. Cossart, “Listeria Monocytogenes: Towards a Complete Picture of Its Physiology and Pathogenesis,” Nature Reviews Microbiology 16, no. 1 (2018): 32–46.

[161] M. Bonazzi, M. Lecuit, and P. Cossart, “Listeria Monocytogenes Internalin and E-Cadherin: From Bench to Bedside,” Cold Spring Harbor Perspectives in Biology 1, no. 4 (2009): a003087.

[162] B. S. Sheridan, Q. M. Pham, Y. T. Lee, L. S. Cauley, L. Puddington, and L. Lefrançois, “Oral Infection Drives a Distinct Population of Intestinal Resident Memory CD8(+) T Cells With Enhanced Protective Function,” Immunity 40, no. 5 (2014): 747–757.

[163] T. Wollert, B. Pasche, M. Rochon, et al., “Extending the Host Range of Listeria Monocytogenes by Rational Protein Design,” Cell 129, no. 5 (2007): 891–902.

[164] E. N. Bou Ghanem, G. S. Jones, T. Myers-Morales, P. D. Patil, A. N. Hidayatullah, and S. E. D'Orazio, “InlA Promotes Dissemination of Listeria Monocytogenes to the Mesenteric Lymph Nodes During Food Borne Infection of Mice,” Plos Pathogens 8, no. 11 (2012): e1003015.

[165] D. Masopust, V. Vezys, E. J. Wherry, D. L. Barber, and R. Ahmed, “Cutting Edge: Gut Microenvironment Promotes Differentiation of a Unique Memory CD8 T Cell Population,” Journal of Immunology 176, no. 4 (2006): 2079–2083.

[166] K. D. Klonowski, K. J. Williams, A. L. Marzo, D. A. Blair, E. G. Lingenheld, and L. Lefrançois, “Dynamics of Blood-Borne CD8 Memory T Cell Migration in Vivo,” Immunity 20, no. 5 (2004): 551–562.

[167] J. P. Daily, A. Minuti, and N. Khan, “Diagnosis, Treatment, and Prevention of Malaria in the US: A Review,” Jama 328, no. 5 (2022): 460–471.

[168] Q. Li, T. Liu, K. Lv, et al., “Malaria: Past, Present, and Future,” Signal Transduction Target Therapy 10, no. 1 (2025): 188.

[169] W. R. Weiss, M. Sedegah, R. L. Beaudoin, L. H. Miller, and M. F. Good, “CD8+ T Cells (Cytotoxic/Suppressors) Are Required for Protection in Mice Immunized With Malaria Sporozoites,” PNAS USA 85, no. 2 (1988): 573–576.

[170] M. G. Overstreet, I. A. Cockburn, Y. C. Chen, and F. Zavala, “Protective CD8 T Cells Against Plasmodium Liver Stages: Immunobiology of an ‘Unnatural’ immune Response,” Immunological Reviews 225 (2008): 272–283.

[171] I. A. Cockburn, S. W. Tse, A. J. Radtke, et al., “Dendritic Cells and Hepatocytes Use Distinct Pathways to Process Protective Antigen From Plasmodium in Vivo,” Plos Pathogens 7, no. 3 (2011): e1001318.

[172] D. L. Woodland and J. E. Kohlmeier, “Migration, Maintenance and Recall of Memory T Cells in Peripheral Tissues,” Nature Reviews Immunology 9, no. 3 (2009): 153–161.

[173] D. Brown Romero, G. E. Finney, M. Dudek, and L. J. Pallett, “Tissue-Resident Memory CD8(+) T Cells: Master Deciphers of the Hepatic Environment,” Nature Reviews Gastroenterology & Hepatology 22, no. 12 (2025): 814–828.

[174] S. W. Tse, I. A. Cockburn, H. Zhang, A. L. Scott, and F. Zavala, “Unique Transcriptional Profile of Liver-Resident Memory CD8+ T Cells Induced by Immunization With Malaria Sporozoites,” Genes and Immunity 14, no. 5 (2013): 302–309.

[175] R. A. Clark, “Resident Memory T Cells in Human Health and Disease,” Science Translational Medicine 7, no. 269 (2015): 269rv1.

[176] G. E. Ryan, J. E. Harris, and J. M. Richmond, “Resident Memory T Cells in Autoimmune Skin Diseases,” Frontiers in Immunology 12 (2021): 652191.

[177] B. Klein, A. C. Billi, L. Abernathy-Close, and J. M. Kahlenberg, “Cutaneous Lupus Erythematosus—From Pathogenesis to Targeted Therapy,” Nature Reviews Rheumatology 21, no. 12 (2025): 703–718.

[178] M. Zeidi, K. L. Chen, J. Patel, et al., “Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials,” Lupus 31, no. 4 (2022): 472–481.

[179] A. W. Armstrong, A. Blauvelt, K. Callis Duffin, et al., “Psoriasis,” Nature Reviews Disease Primers 11, no. 1 (2025): 45.

[180] W. H. Boehncke and M. P. Schön, “Psoriasis,” Lancet 386, no. 9997 (2015): 983–994.

[181] K. Kurihara, T. Fujiyama, P. Phadungsaksawasdi, T. Ito, and Y. Tokura, “Significance of IL-17A-producing CD8(+)CD103(+) Skin Resident Memory T Cells in Psoriasis Lesion and Their Possible Relationship to Clinical Course,” Journal of Dermatological Science 95, no. 1 (2019): 21–27.

[182] P. Phadungsaksawasdi, T. Fujiyama, K. Kurihara, T. Ito, T. Honda, and Y. Tokura, “PD-1 Expression Defines Epidermal CD8(+)CD103(+) T Cells Preferentially Producing IL-17A and Using Skewed TCR Repertoire in Psoriasis,” Journal of Investigative Dermatology 141, no. 10 (2021): 2426–2435, e5.

[183] M. J. Turk and Y. H. Huang, “The Immunology of Vitiligo,” Nature Reviews Immunology (2026): 284–297.

[184] J. Han, Y. Zhao, K. Shirai, et al., “Resident and Circulating Memory T Cells Persist for Years in Melanoma Patients With Durable Responses to Immunotherapy,” Nat Cancer 2, no. 3 (2021): 300–311.

[185] K. Boniface, C. Jacquemin, A. S. Darrigade, et al., “Vitiligo Skin Is Imprinted With Resident Memory CD8 T Cells Expressing CXCR3,” Journal of Investigative Dermatology 138, no. 2 (2018): 355–364.

[186] J. E. Harris, T. H. Harris, W. Weninger, E. J. Wherry, C. A. Hunter, and L. A. Turka, “A Mouse Model of Vitiligo With Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8⁺ T-Cell Accumulation in the Skin,” Journal of Investigative Dermatology 132, no. 7 (2012): 1869–1876.

[187] J. E. Harris, M. Rashighi, N. Nguyen, et al., “Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient With Coexistent Vitiligo and Alopecia Areata (AA),” Journal of the American Academy of Dermatology 74, no. 2 (2016): 370–371.

[188] V. Azzolino, L. Zapata, Jr., and M. Garg, “Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells,” Journal of Investigative Dermatology 141, no. 1 (2021): 182–184, e1.

[189] Z. Szekanecz, I. B. McInnes, G. Schett, S. Szamosi, S. Benkő, and G. Szűcs, “Autoinflammation and Autoimmunity Across Rheumatic and Musculoskeletal Diseases,” Nat Reviews Rheumatology 17, no. 10 (2021): 585–595.

[190] J. S. Smolen, D. Aletaha, A. Barton, et al., “Rheumatoid Arthritis,” Nature Reviews Disease Primers 4 (2018): 18001.

[191] S. Onuora, “Erasing the Memory of Arthritis in Joints,” Nature Reviews Rheumatology 18, no. 1 (2022): 5.

[192] J. Jung, J. S. Lee, Y. G. Kim, et al., “Synovial Fluid CD69(+)CD8(+) T Cells With Tissue-Resident Phenotype Mediate Perforin-dependent Citrullination in Rheumatoid Arthritis,” Clinical and Translational Immunology 9, no. 6 (2020): e1140.

[193] M. H. Chang, A. Levescot, N. Nelson-Maney, et al., “Arthritis Flares Mediated by Tissue-Resident Memory T Cells in the Joint,” Cell Reports 37, no. 4 (2021): 109902.

[194] A. Gao, W. Zhao, R. Wu, et al., “Tissue-resident Memory T Cells: The Key Frontier in Local Synovitis Memory of Rheumatoid Arthritis,” Journal of Autoimmunity 133 (2022): 102950.

[195] F. Zhang, K. Wei, K. Slowikowski, et al., “Defining Inflammatory Cell States in Rheumatoid Arthritis Joint Synovial Tissues by Integrating Single-cell Transcriptomics and Mass Cytometry,” Nature Immunology 20, no. 7 (2019): 928–942.

[196] A. Kaul, C. Gordon, M. K. Crow, et al., “Systemic lupus erythematosus,” Nature Reviews Disease Primers 2 (2016): 16039.

[197] J. S. Tilstra, L. Avery, A. V. Menk, et al., “Kidney-infiltrating T Cells in Murine Lupus Nephritis Are Metabolically and Functionally Exhausted,” Journal of Clinical Investigation 128, no. 11 (2018): 4884–4897.

[198] L. Couzi, P. Merville, C. Deminière, et al., “Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis,” Arthritis and Rheumatism 56, no. 7 (2007): 2362–2370.

[199] S. V. Parikh, S. Almaani, S. Brodsky, and B. H. Rovin, “Update on Lupus Nephritis: Core Curriculum 2020,” American Journal of Kidney Diseases 76, no. 2 (2020): 265–281.

[200] A. Arazi, D. A. Rao, C. C. Berthier, et al., “The Immune Cell Landscape in Kidneys of Patients With Lupus Nephritis,” Nature Immunology 20, no. 7 (2019): 902–914.

[201] E. R. Volkmann, K. Andréasson, and V. Smith, “Systemic Sclerosis,” Lancet 401, no. 10373 (2023): 304–318.

[202] J. H. W. Distler, D. Launay, C. Feghali-Bostwick, A. E. Matei, M. Trojanowska, and J. E. Gudjonsson, “Mechanisms of Fibrotic Tissue Remodelling: Insights From Systemic Sclerosis,” Nature Reviews Rheumatology (2026): 221–238.

[203] J. H. W. Distler, M. Kuwana, S. Assassi, and C. P. Denton, “Emerging Therapies for the Treatment of Systemic Sclerosis,” Nature Reviews Rheumatology 21, no. 10 (2025): 612–625.

[204] N. Altorok and B. Kahaleh, “Epigenetics and Systemic Sclerosis,” Seminars in Immunopathology 37, no. 5 (2015): 453–462.

[205] P. Fuschiotti, A. T. Larregina, J. Ho, C. Feghali-Bostwick, and T. A. Medsger, Jr, “Interleukin-13-Producing CD8+ T Cells Mediate Dermal Fibrosis in Patients With Systemic Sclerosis,” Arthritis and Rheumatism 65, no. 1 (2013): 236–246.

[206] T. A. Wynn, “Fibrotic Disease and the T(H)1/T(H)2 Paradigm,” Nature Reviews Immunology 4, no. 8 (2004): 583–594.

[207] N. Frangogiannis, “Transforming Growth Factor-β in Tissue Fibrosis,” Journal of Experimental Medicine 217, no. 3 (2020): e20190103.

[208] A. M. Gaydosik, T. Tabib, R. Domsic, D. Khanna, R. Lafyatis, and P. Fuschiotti, “Single-Cell Transcriptome Analysis Identifies Skin-specific T-cell Responses in Systemic Sclerosis,” Annals of the Rheumatic Diseases 80, no. 11 (2021): 1453–1460.

[209] H. Shimagami, K. Nishimura, H. Matsushita, et al., “Single-Cell Analysis Reveals Immune Cell Abnormalities Underlying the Clinical Heterogeneity of Patients With Systemic Sclerosis,” Nature Communications 16, no. 1 (2025): 4949.

[210] J. Yu, R. Tang, and K. Ding, “Epigenetic Modifications in the Pathogenesis of Systemic Sclerosis,” Int J Gen Med 15 (2022): 3155–3166.

[211] C. M. Padilla, E. Valenzi, T. Tabib, et al., “Increased CD8+ Tissue Resident Memory T Cells, Regulatory T Cells and Activated Natural Killer Cells in Systemic Sclerosis Lungs,” Rheumatology (Oxford) 63, no. 3 (2024): 837–845.

[212] G. Li, A. T. Larregina, R. T. Domsic, et al., “Skin-Resident Effector Memory CD8(+)CD28(-) T Cells Exhibit a Profibrotic Phenotype in Patients With Systemic Sclerosis,” Journal of Investigative Dermatology 137, no. 5 (2017): 1042–1050.

[213] A. Lleo, G. Q. Wang, M. E. Gershwin, and G. M. Hirschfield, “Primary Biliary Cholangitis,” Lancet 396, no. 10266 (2020): 1915–1926.

[214] H. X. Zhu, S. H. Yang, C. Y. Gao, et al., “Targeting Pathogenic CD8(+) Tissue-Resident T Cells With Chimeric Antigen Receptor Therapy in Murine Autoimmune Cholangitis,” Nature Communications 15, no. 1 (2024): 2936.

[215] G. Mieli-Vergani, D. Vergani, A. J. Czaja, et al., “Autoimmune Hepatitis,” Nature Reviews Disease Primers 4 (2018): 18017.

[216] G. J. Webb, G. M. Hirschfield, E. L. Krawitt, and M. E. Gershwin, “Cellular and Molecular Mechanisms of Autoimmune Hepatitis,” Annual Review of Pathology 13 (2018): 247–292.

[217] Z. You, Y. Li, Q. Wang, et al., “The Clinical Significance of Hepatic CD69(+) CD103(+) CD8(+) Resident-Memory T Cells in Autoimmune Hepatitis,” Hepatology 74, no. 2 (2021): 847–863.

[218] G. G. Kaplan and S. C. Ng, “Globalisation of Inflammatory Bowel Disease: Perspectives From the Evolution of Inflammatory Bowel Disease in the UK and China,” Lancet Gastroenterology Hepatology 1, no. 4 (2016): 307–316.

[219] L. Hracs, J. W. Windsor, J. Gorospe, et al., “Global Evolution of Inflammatory Bowel Disease Across Epidemiologic Stages,” Nature 642, no. 8067 (2025): 458–466.

[220] N. Jaeger, R. Gamini, M. Cella, et al., “Single-cell Analyses of Crohn's Disease Tissues Reveal Intestinal Intraepithelial T Cells Heterogeneity and Altered Subset Distributions,” Nature Communications 12, no. 1 (2021): 1921.

[221] A. Noble, L. Durant, L. Hoyles, et al., “Deficient Resident Memory T Cell and CD8 T Cell Response to Commensals in Inflammatory Bowel Disease,” Journal of Crohns Colitis 14, no. 4 (2020): 525–537.

[222] B. S. Boland, Z. He, M. S. Tsai, et al., “Heterogeneity and Clonal Relationships of Adaptive Immune Cells in Ulcerative Colitis Revealed by Single-Cell Analyses,” Science Immunology 5, no. 50 (2020): eabb4432.

[223] B. Huang, Z. Chen, L. Geng, et al., “Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways,” Cell 179, no. 5 (2019): 1160–1176.e24.

[224] H. Liao, M. C. Hyman, A. E. Baek, K. Fukase, and D. J. Pinsky, “cAMP/CREB-mediated Transcriptional Regulation of Ectonucleoside Triphosphate Diphosphohydrolase 1 (CD39) Expression,” Journal of Biological Chemistry 285, no. 19 (2010): 14791–14805.

[225] H. Beutier, B. Hechler, O. Godon, et al., “Platelets Expressing IgG Receptor FcγRIIA/CD32A Determine the Severity of Experimental Anaphylaxis,” Science Immunology 3, no. 22 (2018): eaan5997.

[226] S. Dadi, S. Chhangawala, B. M. Whitlock, et al., “Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-Like T Cells,” Cell 164, no. 3 (2016): 365–377.

[227] R. D. Schreiber, L. J. Old, and M. J. Smyth, “Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion,” Science 331, no. 6024 (2011): 1565–1570.

[228] B. T. Malik, K. T. Byrne, J. L. Vella, et al., “Resident Memory T Cells in the Skin Mediate Durable Immunity to Melanoma,” Science Immunology 2, no. 10 (2017): eaam6346.

[229] S. L. Park, A. Buzzai, J. Rautela, et al., “Tissue-resident Memory CD8(+) T Cells Promote Melanoma-Immune Equilibrium in Skin,” Nature 565, no. 7739 (2019): 366–371.

[230] M. Enamorado, S. Iborra, E. Priego, et al., “Enhanced Anti-Tumour Immunity Requires the Interplay Between Resident and Circulating Memory CD8(+) T Cells,” Nature Communications 8 (2017): 16073.

[231] F. Gálvez-Cancino, E. López, E. Menares, et al., “Vaccination-Induced Skin-Resident Memory CD8(+) T Cells Mediate Strong Protection Against Cutaneous Melanoma,” Oncoimmunology 7, no. 7 (2018): e1442163.

[232] M. Nizard, H. Roussel, M. O. Diniz, et al., “Induction of Resident Memory T Cells Enhances the Efficacy of Cancer Vaccine,” Nature Communications 8 (2017): 15221.

[233] P. Savas, B. Virassamy, C. Ye, et al., “Single-cell Profiling of Breast Cancer T Cells Reveals a Tissue-Resident Memory Subset Associated With Improved Prognosis,” Nature Medicine 24, no. 7 (2018): 986–993.

[234] T. Duhen, R. Duhen, R. Montler, et al., “Co-expression of CD39 and CD103 Identifies Tumor-Reactive CD8 T Cells in human Solid Tumors,” Nature Communications 9, no. 1 (2018): 2724.

[235] L. Gauthier, S. Corgnac, M. Boutet, et al., “Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8(+) Resident Memory T Cells in Tumors,” Cancer Research 77, no. 24 (2017): 7072–7082.

[236] A. Le Floc'h, A. Jalil, K. Franciszkiewicz, P. Validire, I. Vergnon, and F. Mami-Chouaib, “Minimal Engagement of CD103 on Cytotoxic T Lymphocytes With an E-Cadherin-Fc Molecule Triggers Lytic Granule Polarization via a Phospholipase Cgamma-Dependent Pathway,” Cancer Research 71, no. 2 (2011): 328–338.

[237] K. Franciszkiewicz, A. Le Floc'h, and A. Jalil, “Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention,” Cancer Research 69, no. 15 (2009): 6249–6255.

[238] K. Franciszkiewicz, L. Floc'h A, M. Boutet, I. Vergnon, A. Schmitt, and F. Mami-Chouaib, “CD103 or LFA-1 Engagement at the Immune Synapse Between Cytotoxic T Cells and Tumor Cells Promotes Maturation and Regulates T-Cell Effector Functions,” Cancer Research 73, no. 2 (2013): 617–628.

[239] S. Lamouille, J. Xu, and R. Derynck, “Molecular Mechanisms of Epithelial-Mesenchymal Transition,” Nature Reviews Molecular Cell Biology 15, no. 3 (2014): 178–196.

[240] R. Medzhitov and C. Janeway, Jr, “Innate Immunity,” New England Journal of Medicine 343, no. 5 (2000): 338–344.

[241] J. Banchereau and R. M. Steinman, “Dendritic Cells and the Control of Immunity,” Nature 392, no. 6673 (1998): 245–252.

[242] J. M. Schenkel, K. A. Fraser, L. K. Beura, K. E. Pauken, V. Vezys, and D. Masopust, “T Cell Memory. Resident Memory CD8 T Cells Trigger Protective Innate and Adaptive Immune Responses,” Science 346, no. 6205 (2014): 98–101.

[243] J. M. Schenkel, K. A. Fraser, V. Vezys, and D. Masopust, “Sensing and Alarm Function of Resident Memory CD8(+) T Cells,” Nature Immunology 14, no. 5 (2013): 509–513.

[244] F. E. Dijkgraaf, L. Kok, and T. N. M. Schumacher, “Formation of Tissue-Resident CD8(+) T-Cell Memory,” Cold Spring Harbor Perspectives in Biology 13, no. 8 (2021): a038117.

[245] K. D. Zens, J. K. Chen, and D. L. Farber, “Vaccine-Generated Lung Tissue-Resident Memory T Cells Provide Heterosubtypic Protection to Influenza Infection,” JCI Insight 1, no. 10 (2016): 85832.

[246] A. O. Hassan, N. M. Kafai, I. P. Dmitriev, et al., “A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2,” Cell 183, no. 1 (2020): 169–184, e13.

[247] K. M. Morabito, T. R. Ruckwardt, A. J. Redwood, S. M. Moin, D. A. Price, and B. S. Graham, “Intranasal Administration of RSV Antigen-Expressing MCMV Elicits Robust Tissue-Resident Effector and Effector Memory CD8+ T Cells in the Lung,” Mucosal Immunology 10, no. 2 (2017): 545–554.

[248] H. X. Tan, A. K. Wheatley, R. Esterbauer, et al., “Induction of Vaginal-Resident HIV-specific CD8 T Cells With Mucosal Prime-Boost Immunization,” Mucosal Immunology 11, no. 3 (2018): 994–1007.

[249] I. Uddbäck, E. K. Cartwright, A. S. Schøller, et al., “Long-Term Maintenance of Lung Resident Memory T Cells Is Mediated by Persistent Antigen,” Mucosal Immunol 14, no. 1 (2021): 92–99.

[250] Y. N. Lee, Y. T. Lee, M. C. Kim, A. T. Gewirtz, and S. M. Kang, “A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity Against Future Pandemic Influenza Virus,” Journal of Immunology 196, no. 6 (2016): 2637–2645.

[251] M. Zaric, P. D. Becker, C. Hervouet, et al., “Long-lived Tissue Resident HIV-1 Specific Memory CD8(+) T Cells Are Generated by Skin Immunization With Live Virus Vectored Microneedle Arrays,” Journal of Control Release 268 (2017): 166–175.

[252] X. Zheng, J. D. Oduro, J. D. Boehme, et al., “Mucosal CD8+ T Cell Responses Induced by an MCMV Based Vaccine Vector Confer Protection Against Influenza Challenge,” Plos Pathogens 15, no. 9 (2019): e1008036.

[253] S. Puksuriwong, M. S. Ahmed, R. Sharma, et al., “Modified Vaccinia Ankara-Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue,” Journal of Infectious Diseases 222, no. 5 (2020): 807–819.

[254] A. O. Hassan, J. B. Case, E. S. Winkler, et al., “A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies,” Cell 182, no. 3 (2020): 744–753.e4.

[255] W. B. Alsoussi, J. S. Turner, J. B. Case, et al., “A Potently Neutralizing Antibody Protects Mice Against SARS-CoV-2 Infection,” Journal of Immunology 205, no. 4 (2020): 915–922.

[256] B. Schwarz, K. M. Morabito, T. J. Ruckwardt, et al., “Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses,” ACS Biomaterial Science Engineering 2, no. 12 (2016): 2324–2332.

[257] S. Adnan, R. K. Reeves, J. Gillis, et al., “Persistent Low-Level Replication of SIVΔnef Drives Maturation of Antibody and CD8 T Cell Responses to Induce Protective Immunity Against Vaginal SIV Infection,” Plos Pathogens 12, no. 12 (2016): e1006104.

[258] T. M. Olsen, B. C. Stone, V. Chuenchob, and S. C. Murphy, “Prime-and-Trap Malaria Vaccination To Generate Protective CD8(+) Liver-Resident Memory T Cells,” Journal of Immunology 201, no. 7 (2018): 1984–1993.

[259] A. M. Valencia-Hernandez, W. Y. Ng, N. Ghazanfari, et al., “A Natural Peptide Antigen Within the Plasmodium Ribosomal Protein RPL6 Confers Liver T(RM) Cell-Mediated Immunity Against Malaria in Mice,” Cell Host & Microbe 27, no. 6 (2020): 950–962.e7.

[260] J. M. Richmond, D. S. Bangari, K. I. Essien, et al., “Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis During Vitiligo and May Serve as Biomarkers of Disease,” Journal of Investigative Dermatology 137, no. 2 (2017): 350–358.

[261] È. Ripoll, L. de Ramon, J. Draibe Bordignon, et al., “JAK3-STAT Pathway Blocking Benefits in Experimental Lupus Nephritis,” Arthritis Research & Therapy 18, no. 1 (2016): 134.

[262] Y. Furumoto, C. K. Smith, L. Blanco, et al., “Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction,” Arthritis & Rheumatology 69, no. 1 (2017): 148–160.

[263] C. Berlin, E. L. Berg, M. J. Briskin, et al., “Alpha 4 Beta 7 Integrin Mediates Lymphocyte Binding to the Mucosal Vascular Addressin MAdCAM-1,” Cell 74, no. 1 (1993): 185–195.

[264] W. J. Sandborn, S. Vermeire, H. Tyrrell, et al., “Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program,” Advances in Therapy 37, no. 7 (2020): 3417–3431.

[265] C. Lichnog, S. Klabunde, E. Becker, et al., “Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease,” Frontiers in Pharmacology 10 (2019): 39.

[266] W. J. Sandborn, B. G. Feagan, P. Rutgeerts, et al., “Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease,” New England Journal of Medicine 369, no. 8 (2013): 711–721.

[267] S. Vermeire, S. Danese, W. J. Sandborn, et al., “Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients With Moderate-to-Severe Ulcerative Colitis or Crohn's Disease,” Journal of Crohn's Colitis 18, no. 5 (2024): 708–719.

[268] D. Mauro, X. Lin, E. Pontarini, et al., “CD8(+) Tissue-Resident Memory T Cells Are Expanded in Primary Sjögren's Disease and Can be Therapeutically Targeted by CD103 Blockade,” Annals of the Rheumatic Diseases 83, no. 10 (2024): 1345–1357.

[269] W. J. Sandborn, B. G. Feagan, D. C. Wolf, et al., “Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis,” New England Journal of Medicine 374, no. 18 (2016): 1754–1762.

[270] C. Y. Hsieh, F. L. Hsu, and T. F. Tsai, “Comparison of Drug-Free Remission After the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis,” Dermatology Therapy (Heidelb) 14, no. 9 (2024): 2607–2620.

[271] A. P. Ganesan, J. Clarke, O. Wood, et al., “Tissue-Resident Memory Features Are Linked to the Magnitude of Cytotoxic T Cell Responses in Human Lung Cancer,” Nature Immunology 18, no. 8 (2017): 940–950.

[272] J. Edwards, J. S. Wilmott, J. Madore, et al., “CD103(+) Tumor-Resident CD8(+) T Cells Are Associated With Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment,” Clinical Cancer Research 24, no. 13 (2018): 3036–3045.

[273] C. A. Egelston, C. Avalos, T. Y. Tu, et al., “Resident Memory CD8+ T Cells Within Cancer Islands Mediate Survival in Breast Cancer Patients,” JCI Insight 4, no. 19 (2019): e130000.

[274] J. Clarke, B. Panwar, A. Madrigal, et al., “Single-cell Transcriptomic Analysis of Tissue-Resident Memory T Cells in Human Lung Cancer,” Journal of Experimental Medicine 216, no. 9 (2019): 2128–2149.

[275] J. R. Webb, K. Milne, P. Watson, R. J. Deleeuw, and B. H. Nelson, “Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated With Increased Survival in High-Grade Serous Ovarian Cancer,” Clinical Cancer Research 20, no. 2 (2014): 434–444.

[276] J. R. Webb, K. Milne, and B. H. Nelson, “PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer,” Cancer immunology research 3, no. 8 (2015): 926–935.

[277] H. C. Bösmüller, P. Wagner, J. K. Peper, et al., “Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer,” International Journal of Gynecological Cancer 26, no. 4 (2016): 671–679.

[278] C. A. Hartana, E. Ahlén Bergman, and A. Broomé, “Tissue-Resident Memory T Cells Are Epigenetically Cytotoxic With Signs of Exhaustion in Human Urinary Bladder Cancer,” Clinical and Experimental Immunology 194, no. 1 (2018): 39–53.

[279] C. Jiang, C. C. Chao, J. Li, et al., “Tissue-Resident Memory T Cell Signatures From Single-Cell Analysis Associated With Better Melanoma Prognosis,” Iscience 27, no. 3 (2024): 109277.

[280] C. J. Lim, Y. H. Lee, L. Pan, et al., “Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma,” Gut 68, no. 5 (2019): 916–927.

[281] L. Zhang, X. Yu, L. Zheng, et al., “Lineage Tracking Reveals Dynamic Relationships of T Cells in Colorectal Cancer,” Nature 564, no. 7735 (2018): 268–272.

[282] B. Bengsch, T. Ohtani, O. Khan, et al., “Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells,” Immunity 48, no. 5 (2018): 1029–1045, e5.

[283] L. Cai, Y. Li, J. Tan, L. Xu, and Y. Li, “Targeting LAG-3, TIM-3, and TIGIT for Cancer Immunotherapy,” Journal of Hematology & Oncology 16, no. 1 (2023): 101.

[284] L. P. Andrews, S. C. Butler, J. Cui, et al., “LAG-3 and PD-1 Synergize on CD8(+) T Cells to Drive T Cell Exhaustion and Hinder Autocrine IFN-γ-Dependent Anti-Tumor Immunity,” Cell 187, no. 16 (2024): 4355–4372.e22.

[285] S. L. Topalian, C. G. Drake, and D. M. Pardoll, “Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy,” Cancer Cell 27, no. 4 (2015): 450–461.

[286] C. Lai, G. Coltart, A. Shapanis, et al., “CD8+CD103+ Tissue-Resident Memory T Cells Convey Reduced Protective Immunity in Cutaneous Squamous Cell Carcinoma,” Journal for ImmunoTherapy of Cancer 9, no. 1 (2021): e001807.

[287] C. Sanders, A. S. M. Hamad, S. Ng, et al., “CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC,” Cancers (Basel) 14, no. 6 (2022): 1541.

[288] G. Gabriely, A. P. da Cunha, R. M. Rezende, et al., “Targeting Latency-Associated Peptide Promotes Antitumor Immunity,” Science Immunology 2, no. 11 (2017): eaaj1738.

[289] M. Abd Hamid, H. Colin-York, and N. Khalid-Alham, “Self-Maintaining CD103(+) Cancer-Specific T Cells Are Highly Energetic With Rapid Cytotoxic and Effector Responses,” Cancer Immunology Research 8, no. 2 (2020): 203–216.

[290] S. M. O'Brien, A. Klampatsa, J. C. Thompson, et al., “Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer,” Cancer Immunology Research 7, no. 6 (2019): 896–909.

[291] G. Han, S. L. Lu, A. G. Li, et al., “Distinct Mechanisms of TGF-beta1-Mediated Epithelial-to-Mesenchymal Transition and Metastasis During Skin Carcinogenesis,” Journal of Clinical Investigation 115, no. 7 (2005): 1714–1723.

[292] A. S. MacLeod, R. Rudolph, R. Corriden, I. Ye, O. Garijo, and W. L. Havran, “Skin-Resident T Cells Sense Ultraviolet Radiation-Induced Injury and Contribute to DNA Repair,” Journal of Immunology 192, no. 12 (2014): 5695–5702.

[293] H. Borges da Silva, L. K. Beura, H. Wang, et al., “The Purinergic Receptor P2RX7 Directs Metabolic Fitness of Long-Lived Memory CD8(+) T Cells,” Nature 559, no. 7713 (2018): 264–268.

[294] C. E. Weeden, V. Gayevskiy, C. Marceaux, et al., “Early Immune Pressure Initiated by Tissue-Resident Memory T Cells Sculpts Tumor Evolution in Non-Small Cell Lung Cancer,” Cancer Cell 41, no. 5 (2023): 837–852, e6.

[295] R. Lin, H. Zhang, Y. Yuan, et al., “Fatty Acid Oxidation Controls CD8(+) Tissue-Resident Memory T-Cell Survival in Gastric Adenocarcinoma,” Cancer Immunology Research 8, no. 4 (2020): 479–492.

[296] L. Han, Q. L. Gao, X. M. Zhou, et al., “Characterization of CD103(+) CD8(+) Tissue-resident T Cells in Esophageal Squamous Cell Carcinoma: May be Tumor Reactive and Resurrected by anti-PD-1 Blockade,” Cancer Immunology, Immunotherapy 69, no. 8 (2020): 1493–1504.

[297] A. M. Luoma, S. Suo, Y. Wang, et al., “Tissue-Resident Memory and Circulating T Cells Are Early Responders to Pre-surgical Cancer Immunotherapy,” Cell 185, no. 16 (2022): 2918–2935, e29.

[298] A. Pizzolla, S. P. Keam, I. A. Vergara, et al., “Tissue-Resident Memory T Cells From a Metastatic Vaginal Melanoma Patient Are Tumor-Responsive T Cells and Increase After Anti-PD-1 Treatment,” Journal for ImmunoTherapy of Cancer 10, no. 5 (2022): e004574.

[299] T. C. Wu, K. Xu, R. Banchereau, et al., “Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+ CD8+ Mucosal T-Cell Differentiation and Breast Cancer Rejection,” Cancer Immunology Research 2, no. 5 (2014): 487–500.

[300] S. H. Baumeister, G. J. Freeman, G. Dranoff, and A. H. Sharpe, “Coinhibitory Pathways in Immunotherapy for Cancer,” Annual Review of Immunology 34 (2016): 539–573.

[301] Y. Shen, X. L. Li, Y. X. Li, et al., “Distribution, Phenotype, Functional and Clinical Relevance of CD8(+)CD103(+) Tissue-Resident Memory T Cells in Human Gastric Cancer,” Cancer Immunology, Immunotherapy 71, no. 7 (2022): 1645–1654.

[302] M. Desbois, P. Le Vu, and C. Coutzac, “IL-15 Trans-Signaling With the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists,” Journal of Immunology 197, no. 1 (2016): 168–178.

[303] K. I. Woroniecka, K. E. Rhodin, C. Dechant, et al., “4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers,” Clinical Cancer Research 26, no. 6 (2020): 1349–1358.

[304] X. Yu, K. Harden, L. C. Gonzalez, et al., “The Surface Protein TIGIT Suppresses T Cell Activation by Promoting the Generation of Mature Immunoregulatory Dendritic Cells,” Nature Immunology 10, no. 1 (2009): 48–57.

[305] B. C. Cho, D. R. Abreu, M. Hussein, et al., “Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as a First-Line Treatment for PD-L1-selected Non-Small-Cell Lung Cancer (CITYSCAPE): Primary and Follow-up Analyses of a Randomised, Double-Blind, Phase 2 Study,” The Lancet Oncology 23, no. 6 (2022): 781–792.

[306] K. L. Banta, X. Xu, A. S. Chitre, et al., “Mechanistic Convergence of the TIGIT and PD-1 Inhibitory Pathways Necessitates co-blockade to Optimize Anti-Tumor CD8(+) T Cell Responses,” Immunity 55, no. 3 (2022): 512–526.e9.

[307] K. Nutsch, K. L. Banta, T. D. Wu, et al., “TIGIT and PD-L1 Co-Blockade Promotes Clonal Expansion of Multipotent, Non-Exhausted Antitumor T Cells by Facilitating Co-Stimulation,” Nature Cancer 5, no. 12 (2024): 1834–1851.

[308] X. Chu, W. Tian, Z. Wang, J. Zhang, and R. Zhou, “Co-Inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials,” Molecular Cancer 22, no. 1 (2023): 93.

[309] M. Lauret, E. Joseph, A. Kirilovsky, B. Lecoester, et al., “Chemoradiation Triggers Antitumor Th1 and Tissue Resident Memory-Polarized Immune Responses to Improve Immune Checkpoint Inhibitors Therapy,” Journal for ImmunoTherapy of Cancer 9, no. 7 (2021): e002256.

[310] T. Mori, H. Tanaka, S. Deguchi, et al., “CD103(+) T Cells May Be a Useful Biomarker in Borrmann Type 4 Gastric Cancer,” Cancer Diagnosis and Prognosis 2, no. 3 (2022): 384–390.

[311] Y. Luo, Y. Zong, H. Hua, et al., “Immune-infiltrating Signature-based Classification Reveals CD103(+)CD39(+) T Cells Associate With Colorectal Cancer Prognosis and Response to Immunotherapy,” Frontiers in Immunology 13 (2022): 1011590.

[312] G. Oliveira, A. M. Egloff, A. B. Afeyan, et al., “Preexisting Tumor-resident T Cells With Cytotoxic Potential Associate With Response to Neoadjuvant Anti-PD-1 in Head and Neck Cancer,” Science Immunology 8, no. 87 (2023): eadf4968.

[313] Y. Y. Janjigian, K. Shitara, M. Moehler, et al., “First-Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial,” Lancet 398, no. 10294 (2021): 27–40.

[314] M. Osman, S. L. Park, and L. K. Mackay, “Tissue-Resident Memory T (T(RM)) Cells: Front-Line Workers of the Immune System,” European Journal of Immunology 53, no. 11 (2023): e2250060.

[315] F. Sandoval, M. Terme, M. Nizard, et al., “Mucosal Imprinting of Vaccine-Induced CD8⁺ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors,” Science Translational Medicine 5, no. 172 (2013): 172ra20.

[316] Y. Y. Sun, S. Peng, L. Han, et al., “Local HPV Recombinant Vaccinia Boost Following Priming With an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract,” Clinical Cancer Research 22, no. 3 (2016): 657–669.

[317] F. Oltmanns, A. Vieira Antão, P. Irrgang, et al., “Mucosal Tumor Vaccination Delivering Endogenous Tumor Antigens Protects Against Pulmonary Breast Cancer Metastases,” Journal for ImmunoTherapy of Cancer 12, no. 3 (2024): e008652.

[318] M. Mondini, M. Nizard, T. Tran, et al., “Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer,” Molecular Cancer Therapeutics 14, no. 6 (2015): 1336–1345.

[319] B. M. Andersen and J. R. Ohlfest, “Increasing the Efficacy of Tumor Cell Vaccines by Enhancing Cross Priming,” Cancer Letters 325, no. 2 (2012): 155–164.

[320] H. Xu, M. Yue, R. Zhou, et al., “A Prime-Boost Vaccination Approach Induces Lung Resident Memory CD8+ T Cells Derived From Central Memory T Cells That Prevent Tumor Lung Metastasis,” Cancer Research 84, no. 19 (2024): 3173–3188.

[321] S. Karaki, C. Blanc, T. Tran, et al., “CXCR6 deficiency Impairs Cancer Vaccine Efficacy and CD8(+) Resident Memory T-cell Recruitment in Head and Neck and Lung Tumors,” Journal for ImmunoTherapy of Cancer 9, no. 3 (2021): e001948.

[322] M. V. Dhodapkar and K. M. Dhodapkar, “Tissue-resident Memory-Like T Cells in Tumor Immunity: Clinical Implications,” Seminars in Immunology 49 (2020): 101415.

[323] S. Haddadi, M. Vaseghi-Shanjani, Y. Yao, et al., “Mucosal-Pull Induction of Lung-Resident Memory CD8 T Cells in Parenteral TB Vaccine-Primed Hosts Requires Cognate Antigens and CD4 T Cells,” Frontiers in Immunology 10 (2019): 2075.

[324] H. Shin and A. Iwasaki, “A Vaccine Strategy That Protects Against Genital Herpes by Establishing Local Memory T Cells,” Nature 491, no. 7424 (2012): 463–467.

[325] I. Caminschi, M. H. Lahoud, A. Pizzolla, and L. M. Wakim, “Zymosan by-Passes the Requirement for Pulmonary Antigen Encounter in Lung Tissue-Resident Memory CD8(+) T Cell Development,” Mucosal Immunology 12, no. 2 (2019): 403–412.

[326] T. Zhao, Y. Cai, Y. Jiang, et al., “Vaccine Adjuvants: Mechanisms and Platforms,” Signal Transduction Target Therapy 8, no. 1 (2023): 283.

[327] J. C. Y. Lai, W. K. Cheng, P. D. Hopkins, M. Komba, D. A. Carlow, and J. P. Dutz, “Topical Adjuvant Application During Subcutaneous Vaccination Promotes Resident Memory T Cell Generation,” Journal of Immunology 203, no. 9 (2019): 2443–2450.

[328] T. Kondo, M. Ando, N. Nagai, et al., “The NOTCH-FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory-Like CAR-T Cells,” Cancer Research 80, no. 3 (2020): 471–483.

[329] T. Kondo, Y. Imura, S. Chikuma, et al., “Generation and Application of Human Induced-Stem Cell Memory T Cells for Adoptive Immunotherapy,” Cancer Science 109, no. 7 (2018): 2130–2140.

[330] M. Ando, T. Kondo, W. Tomisato, et al., “Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory-Like CAR T Cells by Resting Them in the Presence of CXCL12 and the NOTCH Ligand,” Cancer Res Commun 1, no. 1 (2021): 41–55.

[331] I. Y. Jung, E. Noguera-Ortega, R. Bartoszek, et al., “Tissue-Resident Memory CAR T Cells With Stem-Like Characteristics Display Enhanced Efficacy Against Solid and Liquid Tumors,” Cell Rep Med 4, no. 6 (2023): 101053.

[332] B. G. Nixon, S. Gao, X. Wang, and L. MO, “TGFβ Control of Immune Responses in Cancer: A Holistic Immuno-Oncology Perspective,” Nature Reviews Immunology 23, no. 6 (2023): 346–362.

[333] E. Batlle and J. Massagué, “Transforming Growth Factor-β Signaling in Immunity and Cancer,” Immunity 50, no. 4 (2019): 924–940.

[334] L. Gorelik and R. A. Flavell, “Immune-mediated Eradication of Tumors Through the Blockade of Transforming Growth Factor-beta Signaling in T Cells,” Nature Medicine 7, no. 10 (2001): 1118–1122.

[335] A. de Folmont, J.-H. Bourhis, S. Chouaib, and S. Terry, “Multifaceted Role of the Transforming Growth Factor ? on Effector T Cells and the Implication for CAR-T Cell Therapy,” Immuno 1, no. 3 (2021): 160–173.

[336] M. Dhainaut, S. A. Rose, G. Akturk, et al., “Spatial CRISPR Genomics Identifies Regulators of the Tumor Microenvironment,” Cell 185, no. 7 (2022): 1223–1239.e20.

[337] M. W. Dukes and G. Krenciute, “Steering CAR T Cell Epigenetic Programs by Tweaking Manufacturing Protocol,” Cell Reports Medicine 4, no. 6 (2023): 101080.

[338] L. Tang, Y. Zheng, M. B. Melo, et al., “Enhancing T Cell Therapy Through TCR-Signaling-Responsive Nanoparticle Drug Delivery,” Nature Biotechnology 36, no. 8 (2018): 707–716.

[339] Y. Q. Xie, H. Arik, L. Wei, et al., “Redox-responsive Interleukin-2 Nanogel Specifically and Safely Promotes the Proliferation and Memory Precursor Differentiation of Tumor-Reactive T-Cells,” Biomaterials Science 7, no. 4 (2019): 1345–1357.

[340] D. V. F. Tauriello, E. Sancho, and E. Batlle, “Overcoming TGFβ-mediated Immune Evasion in Cancer,” Nature Reviews Cancer 22, no. 1 (2022): 25–44.

[341] R. L. Philips, Y. Wang, H. Cheon, et al., “The JAK-STAT pathway at 30: Much Learned, Much More to Do,” Cell 185, no. 21 (2022): 3857–3876.

[342] Q. Sun, X. Zhao, R. Li, et al., “STAT3 regulates CD8+ T Cell Differentiation and Functions in Cancer and Acute Infection,” Journal of Experimental Medicine 220, no. 4 (2023): e20220686.

[343] L. Du, B. Wang, M. Wu, et al., “LINC00926 Promotes Progression of Renal Cell Carcinoma via Regulating miR-30a-5p/SOX4 Axis and Activating IFNγ-JAK2-STAT1 Pathway,” Cancer Letters 578 (2023): 216463.

[344] S. Pei, X. Deng, R. Yang, et al., “Age-related decline in CD8(+) Tissue Resident Memory T Cells Compromises Antitumor Immunity,” Nat Aging 4, no. 12 (2024): 1828–1844.

[345] Y. Zhang, R. Kurupati, L. Liu, et al., “Enhancing CD8(+) T Cell Fatty Acid Catabolism Within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy,” Cancer Cell 32, no. 3 (2017): 377–391.e9.

[346] P. S. Chowdhury, K. Chamoto, A. Kumar, and T. Honjo, “PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8(+) T Cells and Facilitates Anti-PD-1 Therapy,” Cancer Immunology Research 6, no. 11 (2018): 1375–1387.

[347] E. Zhao, T. Maj, I. Kryczek, et al., “Cancer Mediates Effector T Cell Dysfunction by Targeting microRNAs and EZH2 via Glycolysis Restriction,” Nature Immunology 17, no. 1 (2016): 95–103.

[348] T. Honda, M. Ando, J. Ando, et al., “Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers,” Molecular Therapy 28, no. 11 (2020): 2394–2405.

[349] H. Torikai, A. Reik, F. Soldner, et al., “Toward Eliminating HLA Class I Expression to Generate Universal Cells From Allogeneic Donors,” Blood 122, no. 8 (2013): 1341–1349.

[350] K. Ikeda, N. Uchida, T. Nishimura, et al., “Efficient Scarless Genome Editing in Human Pluripotent Stem Cells,” Nature Methods 15, no. 12 (2018): 1045–1047.

[351] G. G. Gornalusse, R. K. Hirata, S. E. Funk, et al., “HLA-E-Expressing Pluripotent Stem Cells Escape Allogeneic Responses and Lysis by NK Cells,” Nature Biotechnology 35, no. 8 (2017): 765–772.

[352] Y. Furukawa, M. Ishii, J. Ando, et al., “iPSC-Derived Hypoimmunogenic Tissue Resident Memory T Cells Mediate Robust Anti-Tumor Activity Against Cervical Cancer,” Cell Rep Med 4, no. 12 (2023): 101327.

[353] T. Kondo, R. Morita, Y. Okuzono, et al., “Notch-Mediated Conversion of Activated T Cells Into Stem Cell Memory-Like T Cells for Adoptive Immunotherapy,” Nature Communications 8 (2017): 15338.

[354] R. Vizcardo, K. Masuda, D. Yamada, et al., “Regeneration of Human Tumor Antigen-Specific T Cells From iPSCs Derived From Mature CD8(+) T Cells,” Cell Stem Cell 12, no. 1 (2013): 31–36.

[355] T. Nishimura, S. Kaneko, A. Kawana-Tachikawa, et al., “Generation of Rejuvenated Antigen-Specific T Cells by Reprogramming to Pluripotency and Redifferentiation,” Cell Stem Cell 12, no. 1 (2013): 114–126.

[356] T. J. Connors, R. Matsumoto, S. Verma, et al., “Site-Specific Development and Progressive Maturation of Human Tissue-Resident Memory T Cells Over Infancy and Childhood,” Immunity 56, no. 8 (2023): 1894–1909.e5.

[357] S. L. Hayward, C. D. Scharer, E. K. Cartwright, et al., “Environmental Cues Regulate Epigenetic Reprogramming of Airway-Resident Memory CD8(+) T Cells,” Nature Immunology 21, no. 3 (2020): 309–320.

[358] S. N. Christo, S. L. Park, S. N. Mueller, and L. K. Mackay, “The Multifaceted Role of Tissue-Resident Memory T Cells,” Annual Review of Immunology 42, no. 1 (2024): 317–345.

[359] N. V. Gavil, K. Cheng, and D. Masopust, “Resident Memory T Cells and Cancer,” Immunity 57, no. 8 (2024): 1734–1751.

[360] K. Okła, D. L. Farber, and W. Zou, “Tissue-resident Memory T Cells in Tumor Immunity and Immunotherapy,” Journal of Experimental Medicine 218, no. 4 (2021): e20201605.

[361] S. Corgnac, I. Malenica, L. Mezquita, et al., “CD103(+)CD8(+) T(RM) Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched With Tc17,” Cell Rep Med 1, no. 7 (2020): 100127.

[362] S. L. Park, M. M. Painter, S. Manne, et al., “Tissue-Resident Exhausted and Memory CD8(+) T Cells Have Distinct Ontogeny, Function and Role in Disease,” Nature Immunology 27, no. 1 (2026): 110–125.

[363] O. Khan, J. R. Giles, S. McDonald, et al., “TOX Transcriptionally and Epigenetically Programs CD8(+) T Cell Exhaustion,” Nature 571, no. 7764 (2019): 211–218.

[364] F. Alfei, K. Kanev, M. Hofmann, et al., “TOX Reinforces the Phenotype and Longevity of Exhausted T Cells in Chronic Viral Infection,” Nature 571, no. 7764 (2019): 265–269.

[365] D. Liu, B. Schilling, D. Liu, et al., “Integrative Molecular and Clinical Modeling of Clinical Outcomes to PD1 Blockade in Patients With Metastatic Melanoma,” Nature Medicine 25, no. 12 (2019): 1916–1927.

[366] G. Yang, S. Cai, M. Hu, et al., “Spatial Features of Specific CD103(+)CD8(+) Tissue-Resident Memory T Cell Subsets Define the Prognosis in Patients With Non-Small Cell Lung Cancer,” Journal of Translational Medicine 22, no. 1 (2024): 27.

[367] L. K. Beura, N. J. Fares-Frederickson, E. M. Steinert, et al., “CD4(+) Resident Memory T Cells Dominate Immunosurveillance and Orchestrate Local Recall Responses,” Journal of Experimental Medicine 216, no. 5 (2019): 1214–1229.

[368] P. A. Szabo, M. Miron, and D. L. Farber, “Location, Location, Location: Tissue Resident Memory T Cells in Mice and Humans,” Science Immunology 4, no. 34 (2019): eaas9673.

[369] Y. M. Son, I. S. Cheon, Y. Wu, et al., “Tissue-resident CD4(+) T Helper Cells Assist the Development of Protective respiratory B and CD8(+) T Cell Memory responses,” Science Immunology 6, no. 55 (2021): eabb6852.

[370] P. Ogongo, L. B. Tezera, A. Ardain, et al., “Tissue-Resident-Like CD4+ T Cells Secreting IL-17 Control Mycobacterium Tuberculosis in the Human Lung,” Journal of Clinical Investigation 131, no. 10 (2021): e142014.

[371] N. D. Glennie, V. A. Yeramilli, D. P. Beiting, S. W. Volk, C. T. Weaver, and P. Scott, “Skin-Resident Memory CD4+ T Cells Enhance Protection Against Leishmania Major Infection,” Journal of Experimental Medicine 212, no. 9 (2015): 1405–1414.

[372] P. Scott, “Long-Lived Skin-Resident Memory T Cells Contribute to Concomitant Immunity in Cutaneous Leishmaniasis,” Cold Spring Harbor Perspectives in Biology 12, no. 10 (2020): a038059.

[373] F. R. Carbone, “Unique Properties of Tissue-Resident Memory T Cells in the Lungs: Implications for COVID-19 and Other Respiratory Diseases,” Nature Reviews Immunology 23, no. 5 (2023): 329–335.

[374] S. Wijeyesinghe, L. K. Beura, M. J. Pierson, et al., “Expansible Residence Decentralizes Immune Homeostasis,” Nature 592, no. 7854 (2021): 457–462.

[375] B. Slütter, N. Van Braeckel-Budimir, G. Abboud, S. M. Varga, S. Salek-Ardakani, and J. T. Harty, “Dynamics of Influenza-Induced Lung-Resident Memory T Cells Underlie Waning Heterosubtypic Immunity,” Science Immunology 2, no. 7 (2017): eaag2031.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.